Norgine’s PEDMARQSI Wins Australian TGA Approval
Norgine has achieved a significant regulatory milestone with the Australian Therapeutic Goods Administration (TGA) approving PEDMARQSI® (anhydrous sodium thiosulfate) for preventing cisplatin-induced hearing loss in pediatric patients. This approval marks an important advancement in protecting young cancer patients from ototoxicity, a serious side effect of chemotherapy.
Norgine’s PEDMARQSI Wins Australian TGA Approval Read More »







